Rigel ( (RIGL) ) has provided an update.
On March 6, 2025, Rigel Pharmaceuticals appointed Dr. Mark J. Frohlich to its board of directors, where he will serve on several committees, including the Corporate Governance, Health Care Compliance Oversight and Nominating Committee, and the Scientific and Clinical Trial Advisory Committee. Dr. Frohlich will receive standard non-employee director compensation, including cash retainers and stock options, and has been deemed independent under relevant governance guidelines, with no conflicts of interest or family ties within the company.
More about Rigel
Rigel Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of small molecule drugs for autoimmune and inflammatory diseases, as well as cancer-related conditions.
YTD Price Performance: 18.48%
Average Trading Volume: 271,098
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $366.5M
For a thorough assessment of RIGL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com